Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (41-50 of 436) with videos related to

Pageof 44
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 17, 2023
Developing Criteria for Health Economic Quality Evaluation ToolDavid D Kim, Lauren A Do, Patricia G Synnott, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Dan Greenberg, Peter J Neumann
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 25, 2022
Health technology assessment for gene therapies in haemophiliaJamie O'Hara, Peter J Neumann,
Value in Health Regional Issues|November 25, 2016
Cost-Effectiveness Analysis Expands its Reach WorldwideDan Greenberg, Peter J Neumann
Health Affairs (Project Hope)|September 10, 2009
Is the United States ready for QALYs?Peter J Neumann, Dan Greenberg
Plos One|May 3, 2019
Adherence to the iDSI reference case among published cost-per-DALY averted studiesJoanna Emerson, Ari Panzer, Joshua T Cohen, et al.
Vaccine|October 17, 2021
Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccinesMadison C Silver, Peter J Neumann, Siyu Ma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 31, 2002
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violationKate A Stewart, Peter J Neumann
The New England Journal of Medicine|April 8, 2011
Listening to Provenge--what a costly cancer treatment says about future Medicare policyJames D Chambers, Peter J Neumann
JAMA Network Open|October 22, 2021
Valuing Alzheimer Disease Therapies-Considering Costs and Benefits Beyond the PatientPei-Jung Lin, Peter J Neumann
Pageof 44

Showing results (41-50 of 436) with videos related to

Sort By:
Pageof 44
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 17, 2023
Developing Criteria for Health Economic Quality Evaluation ToolDavid D Kim, Lauren A Do, Patricia G Synnott, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Dan Greenberg, Peter J Neumann
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 25, 2022
Health technology assessment for gene therapies in haemophiliaJamie O'Hara, Peter J Neumann,
Value in Health Regional Issues|November 25, 2016
Cost-Effectiveness Analysis Expands its Reach WorldwideDan Greenberg, Peter J Neumann
Health Affairs (Project Hope)|September 10, 2009
Is the United States ready for QALYs?Peter J Neumann, Dan Greenberg
Plos One|May 3, 2019
Adherence to the iDSI reference case among published cost-per-DALY averted studiesJoanna Emerson, Ari Panzer, Joshua T Cohen, et al.
Vaccine|October 17, 2021
Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccinesMadison C Silver, Peter J Neumann, Siyu Ma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 31, 2002
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violationKate A Stewart, Peter J Neumann
The New England Journal of Medicine|April 8, 2011
Listening to Provenge--what a costly cancer treatment says about future Medicare policyJames D Chambers, Peter J Neumann
JAMA Network Open|October 22, 2021
Valuing Alzheimer Disease Therapies-Considering Costs and Benefits Beyond the PatientPei-Jung Lin, Peter J Neumann
Pageof 44